tradingkey.logo

GeneDx Holdings Corp

WGS
84.290USD
+0.210+0.25%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
2.44BMarktkapitalisierung
776.72KGV TTM

GeneDx Holdings Corp

84.290
+0.210+0.25%

mehr Informationen über GeneDx Holdings Corp Unternehmen

GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.

GeneDx Holdings Corp Informationen

BörsenkürzelWGS
Name des UnternehmensGeneDx Holdings Corp
IPO-datumSep 04, 2020
CEOStueland (Katherine A)
Anzahl der mitarbeiter1000
WertpapierartOrdinary Share
GeschäftsjahresendeSep 04
Addresse333 Ludlow Street
StadtSTAMFORD
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl06902
Telefon18887291206
Websitehttps://sema4.com/
BörsenkürzelWGS
IPO-datumSep 04, 2020
CEOStueland (Katherine A)

Führungskräfte von GeneDx Holdings Corp

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joshua Ruch
Mr. Joshua Ruch
Independent Director
Independent Director
223.99K
+12924.00%
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Independent Director
Independent Director
33.16K
+12924.00%
Mr. Kevin Feeley
Mr. Kevin Feeley
Chief Financial Officer
Chief Financial Officer
9.43K
+437.00%
Dr. Bryan Dechairo
Dr. Bryan Dechairo
Chief Operating Officer
Chief Operating Officer
5.96K
+5961.00%
Mr. Keith A. Meister
Mr. Keith A. Meister
Independent Director
Independent Director
3.58K
-16553.00%
Mr. Jason Michael Ryan, CPA
Mr. Jason Michael Ryan, CPA
Chairman of the Board
Chairman of the Board
--
--
Mr. Eli D. Casdin
Mr. Eli D. Casdin
Independent Director
Independent Director
--
--
Mr. Richard C. (Rick) Pfenniger, Jr.
Mr. Richard C. (Rick) Pfenniger, Jr.
Independent Director
Independent Director
--
--
Ms. Katherine A. Stueland
Ms. Katherine A. Stueland
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Thomas Fuchs
Dr. Thomas Fuchs
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joshua Ruch
Mr. Joshua Ruch
Independent Director
Independent Director
223.99K
+12924.00%
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Independent Director
Independent Director
33.16K
+12924.00%
Mr. Kevin Feeley
Mr. Kevin Feeley
Chief Financial Officer
Chief Financial Officer
9.43K
+437.00%
Dr. Bryan Dechairo
Dr. Bryan Dechairo
Chief Operating Officer
Chief Operating Officer
5.96K
+5961.00%
Mr. Keith A. Meister
Mr. Keith A. Meister
Independent Director
Independent Director
3.58K
-16553.00%
Mr. Jason Michael Ryan, CPA
Mr. Jason Michael Ryan, CPA
Chairman of the Board
Chairman of the Board
--
--

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Patients with third party insurance
95.02M
81.39%
Institutional customers
17.87M
15.31%
Other
3.22M
2.76%
Self pay patients
629.00K
0.54%
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Patients with third party insurance
95.02M
81.39%
Institutional customers
17.87M
15.31%
Other
3.22M
2.76%
Self pay patients
629.00K
0.54%

Aktionärsstatistik

Aktualisiert: Sat, Jan 31
Aktualisiert: Sat, Jan 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Corvex Management LP
10.58%
Casdin Capital, LLC
10.40%
Icahn School of Medicine at Mount Sinai
4.75%
OPKO Health Inc
4.74%
BlackRock Institutional Trust Company, N.A.
4.56%
Andere
64.96%
Aktionäre
Aktionäre
Anteil
Corvex Management LP
10.58%
Casdin Capital, LLC
10.40%
Icahn School of Medicine at Mount Sinai
4.75%
OPKO Health Inc
4.74%
BlackRock Institutional Trust Company, N.A.
4.56%
Andere
64.96%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
33.56%
Investment Advisor
33.01%
Hedge Fund
30.92%
Corporation
10.65%
Research Firm
6.77%
Individual Investor
1.69%
Pension Fund
0.74%
Venture Capital
0.31%
Sovereign Wealth Fund
0.29%

Institutionelle Beteiligung

Aktualisiert: Wed, Jan 21
Aktualisiert: Wed, Jan 21
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q4
456
30.28M
113.16%
--
2025Q4
496
30.67M
106.12%
-3.46M
2025Q3
446
32.52M
112.51%
-918.42K
2025Q2
397
34.23M
119.24%
+1.02M
2025Q1
398
32.79M
115.46%
-47.86K
2024Q4
341
29.17M
104.22%
+1.72M
2024Q3
289
26.18M
97.50%
+377.48K
2024Q2
262
24.98M
95.33%
+588.25K
2024Q1
260
22.13M
86.19%
+1.41M
2023Q4
271
20.57M
80.67%
-567.28K
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Corvex Management LP
3.06M
10.58%
--
--
Sep 30, 2025
Casdin Capital, LLC
3.01M
10.4%
-38.49K
-1.26%
Sep 30, 2025
Icahn School of Medicine at Mount Sinai
1.37M
4.75%
-1.35M
-49.50%
Feb 21, 2025
OPKO Health Inc
1.37M
4.74%
-800.83K
-36.88%
Nov 20, 2024
BlackRock Institutional Trust Company, N.A.
1.32M
4.56%
+37.99K
+2.97%
Sep 30, 2025
William Blair Investment Management, LLC
1.22M
4.22%
-411.26K
-25.21%
Sep 30, 2025
The Vanguard Group, Inc.
1.17M
4.03%
-10.50K
-0.89%
Sep 30, 2025
Goldman Sachs & Company, Inc.
1.00M
3.47%
+28.59K
+2.94%
Sep 30, 2025
Oracle Investment Management, Inc.
889.95K
3.08%
-32.50K
-3.52%
Sep 30, 2025
Summit Partners Public Asset Management, LLC
823.57K
2.85%
+56.30K
+7.34%
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Global X Genomics & Biotechnology ETF
3.84%
Franklin Genomic Advancements ETF
3.47%
Clough Hedged Equity ETF
2.89%
Clough Select Equity ETF
2.65%
State Street SPDR S&P Health Care Services ETF
2.27%
Harbor Health Care ETF
1.85%
Innovator IBD Breakout Opportunities ETF
1.52%
ARK Genomic Revolution ETF
1.29%
Main Thematic Innovation ETF
1.29%
Invesco Dorsey Wright Healthcare Momentum ETF
1.18%
Mehr Anzeigen
Global X Genomics & Biotechnology ETF
Anteil3.84%
Franklin Genomic Advancements ETF
Anteil3.47%
Clough Hedged Equity ETF
Anteil2.89%
Clough Select Equity ETF
Anteil2.65%
State Street SPDR S&P Health Care Services ETF
Anteil2.27%
Harbor Health Care ETF
Anteil1.85%
Innovator IBD Breakout Opportunities ETF
Anteil1.52%
ARK Genomic Revolution ETF
Anteil1.29%
Main Thematic Innovation ETF
Anteil1.29%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil1.18%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Datum
Ex-Dividendentag
Art
Verhältnis
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
KeyAI